By PTI
NEW DELHI: The COVID-19 Working Group of the NTAGI has really helpful inclusion of the Serum Institute’s Covovax within the nationwide vaccination programme for these aged 12 years and above, official sources stated on Sunday.
India’s drug regulator had accredited Covovax for restricted use in emergency conditions in adults on December 28 and within the 12-17 age group, topic to sure circumstances, on March 9.
The COVID-19 Working Group has now really helpful to the Standing Technical Sub-Committee of the National Technical Advisory Group on Immunisation (NTAGI) that Covovax be included within the nationwide vaccination programme for these aged 12 years and above, sources stated.
Serum Institute of India (SII) Director for Government and Regulatory Affairs Prakash Kumar Singh had written to the Union Health Ministry just lately, requesting for Covovax’s inclusion within the immunisation drive.
“A meeting of the COVID-19 Working Group of the NTAGI took place on April 1 during which data of Covovax was reviewed, after which it recommended that the vaccine can be included in the national COVID-19 vaccination programme for inoculating those aged 12 years and above,” one of many sources stated.
Singh had acknowledged that the Pune-based agency needed to supply Covovax to personal hospitals at Rs 900 per dose plus GST and was ready for instructions to produce it to the Centre.
However, the value of the vaccine for the federal government was not talked about. India started inoculating kids aged 12-14 from March 16. Biological E’s Corbevax is getting used to inoculate them.
In a letter to Union Health Secretary Rajesh Bhushan, Singh was learnt to have stated that non-public corporations, instructional institutes, social organisations, central authorities organisations and public sector undertakings have been making requests for Covovax to inoculate their staffers, households and kids.
“Under the visionary leadership of our CEO Adar C Poonawalla, we have developed, manufactured and obtained emergency use authorisation from our national regulatory authority for one more world-class COVID-19 vaccine, Covovax, for 18 years and above on December 28, and for children in the age group of 12 to 17 years on March 9, 2022,” an official supply quoted Singh as having written within the letter.
